• DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi logo
  • DNDi logo
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • COVID-19
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Global Headquarters
      • DNDi DRC
      • DNDi East Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

How best to prevent and treat COVID-19 in resource-limited settings?

We must accelerate research, share knowledge and data, and prioritize access to affordable tools

Home > Viewpoints

How best to prevent and treat COVID-19 in resource-limited settings?

We must accelerate research, share knowledge and data, and prioritize access to affordable tools

Scientist holding a test tube
3 Apr 2020
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

Viewpoint by

Dr Bernard Pécoul, Executive Director, DNDi

We are all watching with horror as COVID-19 overwhelms the world’s most advanced health systems in Asia, Europe, and North America, leading to tremendous suffering and death. Clinicians, scientists, and communities in low- and middle-income countries in Africa, Asia, Latin America, and the Middle East are bracing themselves. Health systems in some of the most resource-constrained areas are fragile and already under strain – and in crowded slums and townships, social distancing and enhanced hygiene measures to slow the spread will be difficult to implement.

There is a very narrow window for action to help mitigate this disaster, and it is rapidly closing.  

We have few tools to combat this new virus: personal protective equipment and ventilators are in short supply; no therapeutics are yet proven to effectively prevent or treat the disease; and no vaccine is likely for another year or two. Diagnostics are mostly still time-consuming, complex, costly, and lab-based, although our colleagues at the Foundation for Innovative New Diagnostics (FIND) are doing a remarkable job in accelerating the emerging pipeline of rapid tests.

For drugs, the response from the medical and scientific community has also been fast-moving, with new trials and results announced daily. DNDi is closely monitoring the many clinical trials now underway. Particularly encouraging are the WHO-led SOLIDARITY trial for treatment of COVID-19 and the COPCOV trial for prevention, led by the Mahidol Oxford Tropical Medicine Research Unit.

But the overwhelming majority of the 600+ studies taking place worldwide are being conducted in high-income settings, where critical research questions specific to the needs of resource-limited settings are unlikely to be answered.  

While approaches to prevention of new cases – for example pre-exposure prophylaxis for health care workers – may be similar, the tools and approaches to treatment that will work in Berlin or Bangkok may be hard to replicate in Lubumbashi or Lilongwe, especially for severe cases.

What interventions will work best in fragile and overburdened health systems with little to no intensive care capacity?  Will the treatments being investigated today, such as remdesivir – an intravenous drug needing refrigeration – be implementable in settings where hospital capacity is limited, and electricity unreliable?  How can we focus research efforts on treatments that could be effective at an earlier stage, delaying disease progression and the need for intensive care for severe complications?  And what are the implications of widespread underlying co-morbidities, such as malnutrition, HIV, TB, and neglected tropical diseases, on transmission and clinical outcomes?

Only a coordinated response with global cooperation and solidarity, led by experts in low- and middle-income countries, can ensure the rapid action required to generate the needed evidence for new tools.

That is why DNDi has helped launch a new international coalition – the COVID-19 Clinical Research Coalition. Together with the more than 70 other partners that have joined us to accelerate COVID-19 research in resource-limited settings and promote the greatest possible sharing of research knowledge and data.

The Coalition will also push for equitable access to the fruits of scientific progress on COVID-19 – for there are looming questions in this regard.  Will new tools be affordable and available in low- and middle-income countries?  Will intellectual property barriers stymie research collaboration, access, and production? Will stockpiling or export bans leave little to no supply for low and middle-income countries?

At DNDi, it is our view that all new health tools for life-threatening diseases, including COVID-19, must be developed as global public goods, available to all who need them. Never has this imperative been clearer than it is today.

The pandemic we have feared and anticipated for years is now here. The success of the global response will depend upon our collective action to support health research and development that is in the public interest, prioritizes the most vulnerable, and makes sure that the best science serves even the most neglected.

Dr Bernard Pécoul, Executive Director, DNDi

More information

  • COVID-19 Clinical Research Coalition website
  • Comment on the COVID-19 Clinical Research Coalition published in The Lancet
  • Press release on the launch of the COVID-19 Clinical Research Coalition
  • DNDi statement on the COVID-19 pandemic
Policy advocacy COVID-19

Read, watch, share

Loading...
Statements
24 May 2022

DNDi interventions at the 75th World Health Assembly

Hand holding pill
Publications
23 May 2022

Best science for all

Laboratory activities
Press releases
18 May 2022

Consortium formed to discover antivirals for COVID-19 receives NIH funding to develop globally accessible treatments for pandemics

Researcher working in a laboratory setting
News
18 May 2022

Health Journalists from Africa receive grants to report on COVID-19

After a serious outbreak of dengue fever in the Chinatown area of Bangkok in which a man died, the Bangkok Metropolitan Administration came in to fumigate the area and advise locals on possible breeding ground of mosquitos.
Press releases
29 Apr 2022

Ministry of Health, Malaysia and Drugs for Neglected Diseases initiative combine forces to lead the battle against dengue

News
22 Apr 2022

DNDi calls for nominations for a new Audit Committee Member

Microscope and computer
Press releases
20 Apr 2022

DNDi and BenevolentAI collaborate to accelerate life-saving drug discovery research in dengue

Woman looking up
Stories
13 Apr 2022

Early diagnosis and treatment can save millions of lives

VIEW ALL

Help neglected patients

To date, we have delivered nine new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi logo
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License